Cingulate Inc. (CING) News
Follow Cingulate Inc. (CING) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Cingulate gets FDA Complete Response Letter for CTx-1301
Cingulate said the FDA issued a Complete Response Letter for its CTx-1301 NDA on June 1, 2026, and the company is addressing CMC issues with plans to resubmit promptly. Management will present the commercialization and l
REGULATION | Sep 21, 2026, 11:28 AM UTC
L
CINGW CING - Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
CINGW CING - Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
NEWS | Sep 17, 2026, 12:05 PM UTC
L
Cingulate reports Q2 2026 results; CTx-1301 NDA resubmission update
Cingulate Inc. reports its second quarter 2026 financial results and provides an update on CTx-1301 CMC progress toward NDA resubmission and commercial readiness.
EARNINGS | Aug 13, 2026, 12:30 PM UTC
L
CINGW CING - Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology - Click For
CINGW CING - Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
EQUITY | Jul 30, 2026, 12:31 PM UTC
L
Cingulate Joins Russell 3000E Index
Cingulate Inc. (NASDAQ: CING ), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical pr
EQUITY | Jul 02, 2026, 12:30 PM UTC